



IBA signs new contract with the University of Florida Health Proton Therapy Institute

Contract worth approximately \$30 million includes a new Proteus®One system and current equipment upgrades

Louvain-la-Neuve, Belgium, April 8, 2016 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a contract with the University of Florida Health Proton Therapy Institute (UFHPTI) to install a new Proteus®One* system and to upgrade its current proton therapy equipment with IBA's latest technologies.

IBA will equip UFHPTI with its compact Proteus®One system, which includes its next-generation precision technologies of Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities as well as the Philips Ambient Experience. The current proton therapy center, which has treated more than 6,000 patients with IBA technology since 2006, will also be upgraded with the latest in IBA technologies, including PBS, CBCT as well as AdaPT Insight, IBA's platform for adaptive proton therapy and patient-centric workflow.

The contract also includes an operation and maintenance agreement for the Proteus®One system. In total, the contract is worth approximately \$30 million to IBA. The UFHPTI expansion and addition of the Proteus®One system is estimated for completion in 2018. The installation of new PBS and CBCT technologies in the existing proton therapy system will start once the new Proteus®One system is installed.

Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted that UFHPTI, one of the early pioneers in proton therapy, has chosen IBA for its expansion by adding our compact Proteus®One system and upgrading its current system. IBA's commitment to customers is to ensure that all of our users are able to upgrade to the most advanced technology over the lifetime of the equipment, without disruption to patient treatment. We look forward to continuing our collaboration with UFHPTI as we work together to advance the use of proton therapy in the fight against cancer."

Nancy Mendenhall, MD, Medical Director of UF Health Proton Therapy Institute said; "The professional support and responsiveness that IBA has demonstrated throughout our 10 years has resulted in the successful treatment of many patients with proton therapy. We are pleased to be able to expand our clinical service with the addition of the Proteus®One system which will enable even more patients to benefit from cutting-edge proton therapy."

end



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

**Proteus[®]ONE is the brand name of a new configuration of the Proteus[®] 235*

About UF Health Proton Therapy Institute

UF Health Proton Therapy Institute is a nonprofit 501(c)3 organization affiliated with the UF College of Medicine and the UF Health Cancer Center, a Florida Cancer Center of Excellence, dedicated to delivering state-of-the-art cancer treatment and setting new standards for treating and curing cancer. It is an accredited radiation oncology facility by the American College of Radiology. The cancer treatment facility houses both conventional radiation and proton therapy, and delivers proton therapy to 100 patients a day. For more information about the UF Health Proton Therapy Institute, please visit www.floridaproton.org, or call toll-free 877-686-6009.

For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890

Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700

IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+ 1 917 322 2571

mcarey@RxIR.com